Seasonal Affective Disorder

Overview
Epidemiology
Pathophysiology — Circadian Rhythm and DLMO
Serotonin and Melatonin Dysregulation
Clinical Features — Winter vs. Summer SAD
Diagnosis — DSM-5 Criteria
Light Therapy — 10,000 Lux Protocol
Pharmacotherapy — Bupropion XL and SSRIs
Melatonin and Vitamin D
Behavioral and Psychological Interventions
Research Papers
Connections

Overview

Seasonal Affective Disorder (SAD) is a recurrent depressive disorder with a seasonal pattern, most commonly winter-onset (approximately 90% of cases), though summer-onset SAD occurs in roughly 10%. It was first formally described by Rosenthal and colleagues at the National Institute of Mental Health in 1984, following the observation that patients with recurrent winter depression responded dramatically to artificial bright light exposure. This finding was both clinically transformative and scientifically important: it provided the first direct evidence that light could regulate mood in humans.

SAD is classified in DSM-5 as "Major Depressive Disorder with Seasonal Pattern" — it is not a separate diagnosis but a specifier applied to recurrent MDD when episodes cluster reliably by season. Lifetime prevalence ranges from 1–6% in the general population; subsyndromal SAD (often called "winter blues") affects an estimated 14–20% of people in northern latitudes. The disorder is genuinely disabling: occupational impairment, social withdrawal, weight gain of 5–10 lbs per season, hypersomnia of 2 or more hours above usual sleep time, and carbohydrate craving set it apart from typical depression. Left untreated, it recurs every winter for years to decades.

Three treatments have strong evidence: morning bright light therapy (10,000 lux, 20–30 minutes daily), the antidepressant bupropion XL (the only FDA-approved pharmacological prevention), and cognitive-behavioral therapy adapted for SAD. All three are comparably effective; combinations outperform monotherapy in severe cases.

Back to Table of Contents

Epidemiology

Prevalence rises sharply with latitude. Studies estimate roughly 1% of the population in Florida meets SAD criteria, compared to approximately 10% in New Hampshire, and higher rates still in Scandinavia, Alaska, and Iceland. Magnusson and Partonen's epidemiological review noted that Icelandic populations, despite extreme winter photoperiod, show lower-than-expected SAD rates — suggesting genetic adaptation or cultural factors (outdoor activity, fish diet) can partially buffer latitude effects.

The female-to-male ratio is approximately 4:1, one of the most pronounced sex differences in psychiatry. Peak age of onset is in the 20s and 30s, though SAD is recognized in children and adolescents. Family history is a significant risk factor; first-degree relatives of SAD patients have elevated rates of SAD and of major depression generally. Twin studies estimate heritability at approximately 29–68%, with genetic factors influencing both the depressive predisposition and the seasonal timing mechanism. Populations engaged in year-round outdoor activity — subsistence farming communities with high daytime outdoor light exposure — show substantially reduced SAD prevalence, underscoring light exposure as the proximate environmental trigger.

For the seasonal pattern specifier to apply, the seasonal relationship must have been present for at least 2 consecutive years, and seasonal episodes must substantially outnumber non-seasonal major depressive episodes over the individual's lifetime. This prevents misclassification when a person happens to have two consecutive winter depressions due to coincidental life stressors.

Back to Table of Contents

Pathophysiology — Circadian Rhythm and DLMO

The dominant pathophysiological model is the phase-shift hypothesis, developed by Alfred Lewy, Robert Sack, and colleagues. The central claim: in winter-onset SAD, insufficient morning light exposure fails to properly entrain the circadian clock (centered in the suprachiasmatic nucleus, SCN) to the environmental light-dark cycle. This produces a phase delay — the internal clock runs later than it should relative to the sleep-wake schedule.

Dim Light Melatonin Onset (DLMO) is the most reliable circadian phase marker available in clinical research. It marks the time at which pineal melatonin secretion begins under dim-light conditions (typically <10 lux) in the evening. Normal DLMO occurs approximately 2 hours before habitual bedtime. In winter-SAD patients, DLMO is delayed 30–90 minutes beyond this normal relationship — meaning the onset of the melatonin-driven biological night is shifted later, out of alignment with the social and work schedule the patient must keep.

The consequence of this phase mismatch is that patients must wake up and function during their biological night — the interval between their required wake time and their phase-delayed DLMO. This interval is associated with low alertness, dysphoric mood, fatigue, and cognitive slowing. The "circadian misalignment" theory holds that this mismatch, repeated daily for months, is the proximate cause of winter SAD symptoms.

Morning bright light therapy corrects the phase delay by acting as a zeitgeber (time-giver). Light entering the eye in the early morning activates intrinsically photosensitive retinal ganglion cells (ipRGCs) containing the photopigment melanopsin, which is maximally sensitive to short-wavelength blue light (~480 nm). ipRGC axons project via the retinohypothalamic tract directly to the SCN, advancing the circadian phase. Lewy and colleagues demonstrated that morning light produces a significantly greater antidepressant response than evening light in SAD patients, a finding directly predicted by the phase-advance mechanism (PMID 9825013). Evening light, by contrast, can worsen the phase delay.

An alternative model — the photoperiodism hypothesis (Wehr) — proposes that it is the reduction in total daylight duration (photoperiod) in winter, rather than a phase shift per se, that drives SAD. Under this model, the brain's internal representation of season (encoded by the duration of nocturnal melatonin secretion) signals winter conditions that trigger the depressive phenotype. Both mechanisms may operate in different patients or in combination within the same patient.

Back to Table of Contents

Serotonin and Melatonin Dysregulation

Serotonin transporter (SERT) upregulation is a well-replicated finding in winter SAD. Multiple neuroimaging studies using the PET radioligand [11C]DASB — which binds to SERT and provides a measure of transporter density — show significantly elevated SERT binding potential in the midbrain and diencephalon of winter-SAD patients during symptomatic periods. Elevated SERT means more rapid clearance of serotonin from the synapse, producing lower synaptic serotonin concentrations. Praschak-Rieder and colleagues provided key evidence that SERT expression varies seasonally in healthy humans, with higher binding in autumn/winter than spring/summer (PMID 18558852). In SAD patients, this seasonal upregulation is exaggerated and may persist into clinical remission, suggesting a trait vulnerability.

SERT expression appears to be regulated by light through mechanisms that are not fully characterized but may involve direct retinal light input to serotonergic raphe nuclei. Bright light therapy rapidly reduces SERT binding in SAD patients — a neurobiological correlate of the clinical response. SSRIs (serotonin reuptake inhibitors) block SERT pharmacologically, producing the same synaptic serotonin increase through a different mechanism.

Melatonin dynamics in SAD are more nuanced than a simple "too much melatonin" model. Basal melatonin levels during the night do not reliably distinguish SAD patients from controls. What differs is the phase of the melatonin rhythm relative to sleep timing (the DLMO-sleep interval) and, in some patients, a prolonged melatonin secretory tail that extends into morning hours when the patient must be awake and functional. Daytime melatonin — secreted into morning waking hours — directly suppresses alertness and mood.

Dopamine is implicated by PET imaging showing blunted striatal dopamine release in winter SAD. This is consistent with the cardinal symptom of anhedonia (reduced reward-circuit signaling) and provides the neurobiological rationale for bupropion's efficacy — bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI) and also releases dopamine presynaptically at higher doses.

Therapeutic melatonin timing follows directly from the phase-shift model. Low-dose melatonin (0.5 mg — pharmacological rather than supraphysiological) taken 4–6 hours before the patient's DLMO (approximately 14:00–16:00 for most SAD patients) mimics an earlier melatonin onset, advancing the circadian phase. Lewy's "pushing from both ends" strategy combines morning light (phase-advancing the clock from the light end) with afternoon melatonin (phase-advancing from the melatonin end), demonstrating additive effects (PMID 16816135).

Back to Table of Contents

Clinical Features — Winter vs. Summer SAD

Winter-onset SAD (approximately 90% of SAD cases) has a distinctive clinical profile that differs systematically from classical melancholic depression. The episode typically begins in September through November at northern latitudes and remits spontaneously in March through May with increasing daylight. The features are:

Mood: Depressed, dysphoric, hopeless — but with preserved mood reactivity (positive events can transiently lift mood). This "atypical" feature distinguishes winter SAD from melancholic depression.
Sleep: Hypersomnia — patients sleep 10–14 hours per day, often reporting that sleep does not restore energy. The extra sleep is not refreshing. Difficulty getting out of bed in the morning is prominent.
Appetite and weight: Increased appetite, specifically carbohydrate and sweet craving. Weight gain of 5–15 lbs per winter is common. Some patients consciously eat more to self-medicate mood (carbohydrate ingestion transiently raises brain serotonin via insulin-driven tryptophan transport).
Energy: Leaden fatigue — the heaviness of limbs characteristic of atypical depression. Profound energy loss often more disabling than mood itself.
Cognitive: Slowed thinking, difficulty concentrating, impaired short-term memory. Occupational and academic performance declines reliably each winter.
Social: Social withdrawal, hibernation-like behavior, loss of interest in activities previously enjoyed.

Suicidal ideation occurs in approximately 5% of severe cases. The mortality risk from SAD is lower than classical MDD — the seasonally bound, remitting course may protect against accumulated hopelessness — but severity can reach that of major depression requiring urgent treatment.

Summer-onset SAD (approximately 10%) presents with a nearly opposite neurovegetative profile: insomnia rather than hypersomnia, loss of appetite and weight loss rather than hyperphagia, psychomotor agitation rather than slowing, and prominent anxiety and irritability. Episodes begin in late spring or early summer and remit with the onset of autumn. The pathophysiology is less well understood — heat and humidity rather than light deprivation may be the primary trigger. Treatment approaches differ: cool, dark environments; evening activity schedules; and in some cases, air conditioning as a therapeutic intervention. SSRIs and CBT are used pharmacologically and psychologically.

Subsyndromal SAD ("winter blues") — also called sub-SAD — is far more prevalent than full SAD. Patients experience meaningful energy loss, mood lowering, appetite changes, and social withdrawal in winter that fall short of full MDD criteria (duration, severity, or functional impairment thresholds not met). Sub-SAD responds to bright light therapy and represents a substantial public health burden given its high prevalence (up to 14–20% in northern populations).

Back to Table of Contents

Diagnosis — DSM-5 Criteria

In DSM-5, SAD is not a stand-alone diagnosis. It is the "Seasonal Pattern" specifier applied to Major Depressive Disorder, Recurrent — or to Bipolar I or Bipolar II Disorder. The specifier requires all of the following:

A regular temporal relationship exists between the onset of major depressive episodes and a particular time of year (e.g., autumn or winter onset).
Full remissions (or a change from depression to mania/hypomania in bipolar) also occur at a characteristic time of year (e.g., spring remission).
The seasonal pattern episodes must not be better explained by seasonally linked psychosocial stressors (e.g., annual unemployment every winter, anniversary reactions).
At least two major depressive episodes have occurred with the seasonal temporal relationship in the past 2 years, with no non-seasonal episodes during that period.
Seasonal major depressive episodes substantially outnumber non-seasonal major depressive episodes over the individual's lifetime.

The differential diagnosis includes:

Non-seasonal MDD: Recurrent depression that happens to cluster by chance in winter — requires ≥2 years of seasonal pattern to meet specifier criteria.
Bipolar disorder with seasonal pattern: Approximately 20% of bipolar patients show a seasonal pattern — depressive episodes in autumn/winter, hypomanic or manic episodes in spring/summer. Distinguishing SAD from bipolar is critical before initiating antidepressant monotherapy, which carries manic-switch risk in bipolar patients. Screening for past hypomanic symptoms is mandatory.
Hypothyroidism: Fatigue, weight gain, cognitive slowing, and depression in winter can mimic SAD. TSH should be checked in all new SAD presentations; subclinical hypothyroidism worsens in winter.
Vitamin D deficiency: Profound winter fatigue and low mood; check 25-OH-D as part of the initial workup.
Normal winter sleepiness: Increased appetite and sleep in winter are common human seasonal adaptations and do not constitute SAD unless accompanied by significant mood disturbance and functional impairment.

Back to Table of Contents

Light Therapy — 10,000 Lux Protocol

Morning bright light therapy is the first-line treatment for winter-onset SAD, supported by the strongest evidence base and endorsed by all major psychiatric guidelines. It works rapidly — most patients notice improvement within 3–7 days — and is free of the systemic side effects of antidepressants.

Standard protocol:

Device: Light box producing 10,000 lux of full-spectrum fluorescent or LED light at the prescribed distance (typically 12 inches). The device must be positioned at face level or slightly above, not below. UV-filtered boxes are preferred to reduce any theoretical retinal UV exposure.
Duration: 20–30 minutes per session at 10,000 lux. Longer sessions at lower lux (e.g., 2,500 lux for 1–2 hours) are equivalent by total lux-minutes received.
Timing: Within 30–60 minutes of awakening, before 08:00 if possible. Morning timing is critical — the circadian phase-advance effect depends on light exposure during the rising phase of the core body temperature rhythm. Evening use delays the circadian clock and can worsen or prolong episodes.
Eye position: Eyes open and directed toward the light, but not staring directly at it. Normal activities (reading, eating breakfast, working) are appropriate during the session.
Season: Begin in early autumn at the onset of symptoms and continue throughout the winter until natural light increases in spring (typically March–April at northern US latitudes). Abrupt discontinuation mid-winter leads to rapid relapse, often within days.

Efficacy: Meta-analyses confirm response rates of 50–80%. Terman and colleagues' landmark RCTs (PMID 9825013; PMID 18478116) established morning bright light as superior to placebo dim light conditions and superior to evening bright light. Lam et al. (PMID 16815382) found light therapy equivalent in efficacy to fluoxetine 20 mg at 8 weeks; the combination of both was superior to either alone, particularly for severe episodes.

Side effects: Generally mild and transient — headache (15%), eyestrain (10%), nausea (5%), agitation or mild hypomania (rare but important to monitor in patients with bipolar spectrum). In bipolar patients, morning light can precipitate hypomania or mania; shorter sessions, later timing, and mood monitoring are required. Patients with retinal disorders (macular degeneration, diabetic retinopathy), history of eye surgery, or those taking photosensitizing medications (lithium, certain antibiotics, St. John's Wort) should have an ophthalmologic evaluation before starting light therapy (PMID 26867988).

Blue-enriched light: Because melanopsin-containing ipRGCs are maximally sensitive to ~480 nm blue light, blue-enriched white light devices (1,000–2,500 lux) may achieve equivalent circadian phase-advance effects with shorter exposure times. Some patients prefer these lower-intensity blue-enriched devices for convenience. However, theoretical concerns about long-term retinal effects of high-intensity blue light in older patients have not been resolved, and full-spectrum devices remain the standard.

Dawn simulators: Devices that produce a gradual 30–90 minute brightening of bedroom light before awakening, mimicking the natural dawn signal. Terman and colleagues have shown dawn simulation can reduce depressive symptoms and improve morning awakening quality. Dawn simulators are a useful adjunct, particularly for patients who struggle with the abrupt alarm-clock awakening that morning light therapy requires.

Back to Table of Contents

Pharmacotherapy — Bupropion XL and SSRIs

Bupropion XL (Wellbutrin XL) is the only medication with an FDA-approved indication specifically for prevention of recurrent winter-pattern SAD (approved 2006). This is a prevention indication — bupropion is initiated in early autumn before symptom onset rather than treating established depression. Key prescribing details:

Dosing: Begin at 150 mg/day for 1 week, then increase to 300 mg/day (the target dose). Some patients require only 150 mg.
Timing of initiation: Start in September or at the first appearance of prodromal symptoms (fatigue, increased sleep need, carbohydrate craving), before full depression develops.
Duration: Continue through spring remission, then taper and discontinue. Restart the following autumn.
Mechanism: Norepinephrine-dopamine reuptake inhibitor (NDRI) — distinct from SSRIs. Dopamine pathway engagement is likely key to efficacy in the dopamine-deficient SAD phenotype.
Number needed to treat (NNT) for prevention: Approximately 4 — meaning 1 in 4 patients treated is spared a depressive episode they would otherwise have had.
Contraindications: Active seizure disorder or history of seizures; eating disorders (bulimia nervosa, anorexia nervosa — seizure threshold lowered by electrolyte disturbances); abrupt discontinuation of alcohol or benzodiazepines; concomitant use of MAOIs. Bupropion lowers seizure threshold in a dose-dependent manner (Modell et al., PMID 18165466).

SSRIs have a robust evidence base for treating established winter SAD, though none carry a prevention indication. Fluoxetine 20 mg and sertraline are most studied:

Lam et al. (PMID 16815382) in a head-to-head Lancet trial found fluoxetine 20 mg and 10,000 lux morning light therapy equally effective at 8 weeks in winter SAD; the combination was superior to either alone in severely depressed patients.
SSRIs take 4–6 weeks to achieve full antidepressant effect — substantially slower than light therapy's 1–2 week response. For patients who need rapid relief, light therapy is preferred as first-line or concurrent start.
Paroxetine has been shown effective in SAD RCTs but its discontinuation syndrome and anticholinergic burden limit its use.
Escitalopram and sertraline are reasonable alternatives when fluoxetine is not tolerated.

Combination therapy: For moderate-to-severe SAD, combining light therapy with an antidepressant produces better outcomes than either modality alone. The Lam et al. Lancet trial is the landmark evidence for this approach. Clinically, light therapy and bupropion can be combined, though the combination has not been specifically studied in a powered RCT.

MAOIs: Phenelzine and tranylcypromine were historically used for the "atypical depression" features of winter SAD (hypersomnia, hyperphagia, mood reactivity, leaden paralysis — which atypical MAOIs treat preferentially). They remain effective but are now rarely used as first-line agents due to dietary tyramine restrictions, drug interaction risks, and the availability of better-tolerated alternatives.

Back to Table of Contents

Melatonin and Vitamin D

Melatonin: The key insight from phase-shift research is that melatonin's therapeutic utility depends critically on timing — taken at the wrong time, supplemental melatonin reinforces rather than corrects the phase delay. The standard over-the-counter use pattern (high-dose melatonin at bedtime to promote sleep) is counterproductive in winter SAD, where bedtime melatonin extends the already-prolonged nocturnal melatonin window without advancing phase.

The therapeutically effective approach uses low-dose (0.5 mg, not the 3–10 mg sold in stores) melatonin taken in the afternoon — approximately 4–6 hours before the patient's DLMO, which translates to roughly 14:00–16:00 for most winter-SAD patients. This afternoon low-dose melatonin mimics an earlier internal melatonin onset, signaling the circadian clock to advance. Lewy et al. (PMID 16816135) demonstrated in a controlled study that afternoon melatonin combined with morning bright light produced superior antidepressant effects compared to light therapy alone in winter SAD patients with confirmed circadian phase delay. DLMO measurement (via serial saliva or plasma collection) can be used to individualize melatonin timing, though this is available mainly in research settings.

Vitamin D: The epidemiological association between vitamin D insufficiency and winter depression is well-established. Reduced solar UVB exposure in winter, combined with the indoor lifestyle of winter SAD, reliably produces vitamin D insufficiency at northern latitudes. Multiple studies find lower serum 25-hydroxyvitamin D levels in SAD patients than in matched controls.

However, the Cochrane review by Nussbaumer et al. (PMID 24300855) and subsequent RCTs of vitamin D supplementation for SAD have yielded inconsistent results — some trials show benefit, others no effect beyond placebo. The available evidence does not support vitamin D supplementation as a standalone SAD treatment. The causal direction is uncertain: low vitamin D may be a consequence of winter indoor behavior (which itself reflects SAD-driven social withdrawal) rather than a cause of the mood disorder.

The practical clinical approach is to measure 25-OH-D in all new SAD presentations and supplement to the 40–60 ng/mL range if deficient, because vitamin D deficiency independently produces fatigue, musculoskeletal discomfort, and cognitive slowing that worsen the overall symptom burden — regardless of whether it specifically treats the SAD mechanism. Vitamin D does not substitute for light therapy or pharmacotherapy in established SAD.

Back to Table of Contents

Behavioral and Psychological Interventions

Cognitive-behavioral therapy adapted for SAD (CBT-SAD) was manualized by Kelly Rohan and colleagues to address the specific cognitive patterns and behavioral avoidance that perpetuate and worsen winter SAD. The treatment combines two main components: behavioral activation (deliberately scheduling pleasurable, engaging activities during the winter months to counteract the hibernation drive and withdrawal) and cognitive restructuring (identifying and challenging automatic negative seasonal thoughts such as "I always get depressed in winter and there's nothing I can do," "I should hibernate until spring," or "my life is worthless in winter").

In a landmark RCT, Rohan et al. (PMID 15863378) found CBT-SAD equivalent in efficacy to morning bright light therapy at the end of the acute winter treatment period. More importantly, a follow-up study at 2 years (PMID 25919630) found that CBT-SAD produced significantly better relapse prevention than light therapy alone — suggesting that by addressing the cognitive and behavioral patterns that amplify winter symptoms, CBT-SAD creates a more durable change than the purely biological light-therapy intervention. This has meaningful clinical implications: CBT-SAD may be particularly appropriate for patients who want a treatment that reduces future vulnerability rather than requiring indefinite annual light therapy.

Exercise has consistent evidence as an effective antidepressant in major depression generally, with effect sizes comparable to pharmacotherapy in meta-analyses. In winter SAD specifically, morning outdoor exercise provides both the mood and circadian benefits of aerobic activity and the phase-advancing stimulus of outdoor morning light — even on overcast days, outdoor light exceeds indoor artificial lighting by 10–100-fold at any latitude. Prescribing 30–60 minutes of brisk outdoor morning activity 3–5 times per week combines exercise and natural light therapy in a single intervention without additional cost.

Sleep hygiene and circadian anchoring are essential behavioral supports. Consistent awakening at the same time every day — including weekends — is the single most powerful behavioral zeitgeber available. Patients with hypersomnia have a strong impulse to "catch up" on sleep on weekends, but variable wake times destabilize the circadian clock and worsen phase delay. Prescribing a fixed morning wake time (even when it feels difficult) is a non-negotiable behavioral component of any SAD treatment plan.

Oversleeping paradoxically worsens winter SAD fatigue. Sleeping 10–14 hours per day does not restore energy in SAD (unlike recovery sleep in genuine sleep deprivation) and instead reinforces the phase delay and circadian misalignment. Patients should understand this mechanism — sleep does not fix SAD, it perpetuates it when excessive.

Dietary modifications with modest evidence in SAD include moderating refined carbohydrate intake (to reduce reactive hypoglycemia that can worsen energy fluctuations), omega-3 fatty acid supplementation (EPA-predominant formulations have the best evidence for depression), and avoiding alcohol (which is frequently used as self-medication in winter SAD but disrupts sleep architecture and worsens morning functioning).

Back to Table of Contents